公开(公告)号：US09884075B2

公开(公告)日：2018-02-06

申请号：US14597908

申请日：2015-01-15

Applicant: California Institute of Technology

Inventor： Michael T. Bethune ,  Marvin H. Gee ,  David Baltimore

IPC: A61K48/00 ,  A61K35/26 ,  A61K35/28 ,  A61K35/16 ,  A61K35/17 ,  C07K14/725

CPC classification number: A61K35/17 ,  C07K14/7051

Abstract: Disclosed herein are genetically engineered T cell receptors, and methods, vectors, and genetically engineered T cells related to genetically engineered T cell receptors.

公开(公告)号：US20200309765A1

公开(公告)日：2020-10-01

申请号：US16633451

申请日：2018-07-24

Applicant: Michael T. BETHUNE ,  David BALTIMORE ,  California Institute of Technology ,  PACT PHARMA, INC.

Inventor： Michael T. Bethune ,  Jocelyn T. Kim ,  David Baltimore ,  Guideng Li ,  Stephanie Wong

IPC: G01N33/50 ,  G01N33/566 ,  G06F16/27

Abstract: Disclosed herein are trogocytosis based TCR ligand discovery platforms and methods of using the same, trogocytosis based TCR discovery platforms and methods of using the same, and trogocytosis based ligand discovery platforms and methods of using the same. Also disclosed herein are isolated cells, nucleotides, sequences, and sequence databases produced using trogocytosis based discovery platforms.

公开(公告)号：US12066430B2

公开(公告)日：2024-08-20

申请号：US16633451

申请日：2018-07-24

Applicant: California Institute of Technology

Inventor： Michael T. Bethune ,  Jocelyn T. Kim ,  David Baltimore ,  Guideng Li ,  Stephanie Wong

IPC: G01N33/50 ,  G01N33/566 ,  G06F16/27

CPC classification number: G01N33/505 ,  G01N33/566 ,  G06F16/27

Abstract: Disclosed herein are trogocytosis based TCR ligand discovery platforms and methods of using the same, trogocytosis based TCR discovery platforms and methods of using the same, and trogocytosis based ligand discovery platforms and methods of using the same. Also disclosed herein are isolated cells, nucleotides, sequences, and sequence databases produced using trogocytosis based discovery platforms.

公开(公告)号：US20210324035A1

公开(公告)日：2021-10-21

申请号：US17273192

申请日：2019-09-04

Applicant: The Regents of the University of California ,  California Institute of Technology ,  The Olivia Newton-John Cancer Research Institute

Inventor： Owen N. Witte ,  Jami McLaughlin Witte ,  Antoni Ribas ,  Lili Yang ,  Michael T. Bethune ,  Jonathan Cebon ,  Katherine Woods ,  Ashley J. Knights ,  David Baltimore

IPC: C07K14/725 ,  A61K35/17 ,  C12N15/86 ,  C12N5/0783 ,  A61P35/00

Abstract: Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.